🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ResMed Inc. RMD SPXR3KPHARMA

Healthcare · Medical Instruments & Supplies · United States
https://www.resmed.com
Company Profile ↓
$228.35
-20.01% 1Y
Mkt Cap$33.12B
P/E23.16
P/B4.74
Div. Yield1.07%
52W High$290.65
52W Low$182.30
Book Value$44.76
EPS (TTM)$9.86

Company Overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 25.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 23.5%.

Consistent Profit Growth

Net profit has compounded at 15.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.4% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 23.2, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 27.4%.

Recent Developments

  • Jun 2025 Revenue of $5.15B (+9.8% YoY); net profit $1.40B.
  • Trailing 12 Months Year-on-year growth — revenue +10.8%, earnings +10.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.4%, profit CAGR 15.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.36%
1 Year:10.80%

Compounded Profit Growth

5 Years:15.16%
1 Year:10.50%

Stock Price Performance

1 Year:-20.01%
6 Months:-9.17%
3 Months:+16.82%
1 Month:+2.58%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 43% of range
$182.30 $290.65
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)53.58 · Neutral
Price Performance
1M+2.58%
3M+16.82%
6M-9.17%
1Y-20.01%
Valuation vs Sector

P/E of 23.16 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 25.2%.
  • Healthy ROCE of 23.5%.
  • Excellent profit margin of 27.4%.
  • Compounding revenue at 11.4% over 5 years.
  • Profit CAGR of 15.2% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
23.16
Industry PE
25.17
Forward P/E
17.31
PEG Ratio
1.33
Book Value
$44.76
Price to Book
4.74
P/S
5.55
EV/EBITDA
14.89
Dividend Yield
1.07%

Growth (CAGR)

Revenue 5Y
11.36%
Profit 5Y
15.16%
Revenue (YoY)
10.80%
Earnings (YoY)
10.50%

Profitability & Returns

ROCE
23.55%
ROE
25.25%
ROA
14.71%
Profit Margin
27.44%
Op Margin
35.33%
Gross Margin
62.18%
EPS (Latest Qtr)
$2.74
EPS (TTM)
$9.86

Balance Sheet & Liquidity

Debt/Equity
0.13
Quick Ratio
2.00
Current Ratio
3.01
Debt
$843.17M
Total Assets
$8.78B
Current Assets
$3.51B
Working Capital
$2.49B

Ownership

Promoter Holding
0.50%
Chg in Prom Hold
-0.01%
FII / Inst Holding
71.53%
Chg in FII Hold
-0.10%

Financial Snapshot

Enterprise Value
$33.12B
Total Revenue (TTM)
$5.54B
EBITDA
$2.12B
Free Cash Flow
$1.45B
Operating Cash Flow
$1.89B
Shares Outstanding
145.06M
Gross Margin
62.18%
Payout Ratio
22.47%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RMD ResMed Inc. SPXR3KPHARMA 228.35 23.16 $33.12B 1.07% 23.55% 25.25% 11.36% 15.16%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Dec 2013Mar 2014Sep 2014Dec 2014Mar 2015Sep 2015Dec 2015Mar 2016Sep 2016Dec 2016Mar 2017Sep 2017Dec 2017Mar 2018Sep 2018Dec 2018Mar 2019Sep 2019Dec 2019Mar 2020Sep 2020Dec 2020Mar 2021Sep 2021Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Dec 2023Mar 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------------681.06M736.16M769.46M751.94M800.01M768.77M904.01M894.87M864.50M950.29M1.03B1.12B1.10B1.16B1.20B--1.29B1.35B1.34B1.42B1.43B
Cost of Revenue -----------------------------------525.33M527.92M514.76M544.08M540.43M
Gross Profit 227.98M248.76M251.79M237.31M263.22M251.43M238.62M266.51M259.88M269.18M309.07M299.71M305.61M349.79M344.30M343.09M374.53M380.97M391.62M427.13M449.66M438.66M462.48M447.26M506.29M504.32M491.20M540.81M579.72M617.75M600.06M646.93M692.78M--766.41M820.07M820.82M878.72M890.98M
Operating Expenses -----------------------------------340.14M363.50M358.47M381.13M391.17M
Operating Income 96.88M105.02M104.70M94.67M109.15M105.87M98.03M107.98M104.31M94.15M96.89M107.40M112.56M146.02M136.37M144.13M157.08M156.98M171.10M197.81M217.50M216.90M221.72M223.43M261.91M248.71M234.26M275.74M280.19M300.67M289.00M275.09M374.58M--426.27M456.57M462.35M497.60M499.81M
EBITDA -----------------------------------478.18M530.86M520.02M559.92M568.84M
Interest Expense ----------------------------------------
Pretax Income -----------------------------------417.69M458.05M446.79M496.15M502.31M
Tax Provision -----------------------------------52.65M78.35M98.26M103.56M103.58M
Net Income 80.93M86.64M89.97M83.26M91.18M90.98M82.92M95.58M90.79M76.11M76.74M87.82M86.12M9.53M110.12M105.74M124.64M105.42M120.15M160.55M163.14M178.37M179.51M-78.48M203.61M201.75M179.01M210.48M224.91M232.50M219.42M208.80M300.49M--365.04M379.70M348.54M392.59M398.73M
Diluted EPS 0.560.600.630.580.640.640.580.680.640.540.540.620.600.070.760.730.860.730.831.101.121.221.23-0.541.391.371.221.431.531.581.491.422.04--2.482.582.372.682.74
R&D Expense 27.36M29.54M29.53M30.02M29.29M27.02M27.19M28.97M28.11M34.45M38.19M35.13M37.41M40.64M37.43M38.79M43.11M47.61M48.03M49.94M51.45M54.53M54.94M55.94M59.95M62.51M66.80M63.19M69.87M76.44M75.71M73.88M77.07M79.52M81.37M83.94M-87.32M90.97M94.27M

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Revenue 920.74M1.09B1.24B1.37B1.51B1.55B1.68B1.84B2.07B2.34B2.61B2.96B3.20B3.58B4.22B4.69B5.15B
Gross Profit 553.80M655.48M741.33M820.74M940.66M989.79M1.01B1.07B1.20B1.33B1.49B1.72B1.84B2.02B2.36B2.66B3.05B
Operating Income 190.31M240.38M266.92M294.41M354.82M405.09M409.24M428.95M425.80M541.83M579.26M809.66M903.68M1.00B1.13B1.32B1.69B
Net Income 146.45M190.09M226.99M254.85M307.13M345.27M352.89M352.41M342.28M315.59M404.59M621.67M474.50M779.44M897.56M1.02B1.40B
Diluted EPS 0.951.231.441.712.102.392.472.492.402.192.804.273.245.306.096.929.51
R&D Expense 63.06M75.20M92.01M109.73M120.12M118.23M114.86M118.65M144.47M155.15M180.65M201.95M225.28M253.57M287.64M307.52M331.28M

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Assets --1.63B2.07B2.14B2.21B2.36B2.18B3.26B3.47B3.06B4.11B4.59B-5.10B6.75B6.87B8.17B
Current Assets --------------1.93B2.37B2.36B3.51B
Cash & Equivalents 321.08M415.65M488.78M735.27M809.54M876.05M905.73M717.25M731.43M821.93M188.70M147.13M463.16M-273.71M227.89M238.36M1.21B
Inventory --------------743.91M998.01M822.25M927.71M
Receivables --------------575.95M704.91M837.27M939.49M
Total Liabilities --338.86M338.19M530.24M600.21M602.71M594.47M1.56B1.51B1.00B2.04B2.09B-1.74B2.62B2.01B2.21B
Current Liabilities --312.67M208.84M252.85M574.05M269.56M266.46M637.99M360.13M511.25M555.99M602.76M-689.30M758.53M910.65M1.02B
Long Term Debt --0100.00M250.78M769.00K300.77M300.59M873.33M1.08B269.99M1.26B1.16B-765.33M1.43B697.31M658.39M
Total Debt --------------917.55M1.58B873.93M851.81M
Total Equity 1.08B1.12B1.29B1.73B1.61B1.61B1.76B1.59B1.69B1.96B2.06B2.07B2.50B-3.36B4.13B4.86B5.97B
Shares Outstanding --------------188.25M188.90M189.57M190.31M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Operating Cash Flow 238.88M188.21M283.19M383.16M402.82M--547.93M414.05M505.03M459.05M802.25M736.72M351.15M693.30M1.40B1.75B
Investing Cash Flow -109.30M-58.31M-76.51M-101.61M-78.00M---1.13B-81.89M-101.82M-1.08B-179.86M-158.46M-229.92M-1.16B-269.78M-200.04M
Financing Cash Flow 1.87M-61.13M-79.34M-177.10M-153.93M--612.58M-262.87M-1.03B580.64M-317.29M-764.63M-128.36M422.87M-1.12B-606.25M
Capital Expenditure -109.69M-56.85M-66.61M-47.13M-63.58M-72.72M-62.50M-58.53M-62.22M-62.58M-68.71M-95.33M-102.71M-134.84M-119.67M-99.46M-89.86M
Free Cash Flow 129.19M131.36M216.58M336.02M339.24M--489.40M351.83M442.44M390.34M706.92M634.01M216.31M573.63M1.30B1.66B
Share Buybacks 68.59M131.08M163.34M392.74M186.26M202.17M160.30M102.06M-53.80M22.84M--00150.01M300.02M
Dividends Paid ----97.20M141.52M157.26M168.13M186.35M199.50M211.71M225.09M226.71M245.34M258.28M282.32M310.88M

Ratios (Annual)

Figures in %.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Gross Margin % 60.1%60.0%59.6%60.0%62.1%63.7%60.2%58.0%58.1%57.0%57.3%58.1%57.5%56.6%55.8%56.7%59.4%
Operating Margin % 20.7%22.0%21.5%21.5%23.4%26.1%24.4%23.3%20.6%23.2%22.2%27.4%28.3%28.0%26.8%28.2%32.7%
Net Margin % 15.9%17.4%18.3%18.6%20.3%22.2%21.0%19.2%16.6%13.5%15.5%21.0%14.8%21.8%21.3%21.8%27.2%
ROE % 13.1%14.8%13.1%15.9%19.1%19.6%22.2%20.8%17.5%15.3%19.5%24.9%-23.2%21.7%21.0%23.5%
ROCE % -18.3%14.4%15.6%21.7%19.4%21.4%16.4%13.7%21.2%16.3%20.3%-22.7%18.9%22.1%23.6%

Shareholding Pattern

Insiders
0.50%
Institutions
71.53%
Public Float
71.89%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.54% 12.32M $2.96B
2 Vanguard Capital Management LLC 6.57% 9.47M $2.28B
3 Vanguard Portfolio Management LLC 5.49% 7.91M $1.90B
4 State Street Corporation 4.63% 6.68M $1.61B
5 Geode Capital Management, LLC 3.02% 4.35M $1.05B
6 Bank Of New York Mellon Corporation 2.91% 4.20M $1.01B
7 First Trust Advisors LP 1.58% 2.28M $547.64M
8 Invesco Ltd. 1.43% 2.06M $495.94M
9 Morgan Stanley 1.34% 1.93M $463.58M
10 Northern Trust Corporation 1.18% 1.70M $407.76M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RMD

Yahoo Finance hu, 27 Aug 2026

Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference

SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanley Global Heal…

Yahoo Finance ue, 25 Aug 2026

ResMed Stock: Analyst Estimates & Ratings

Although ResMed has underperformed the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Yahoo Finance ue, 25 Aug 2026

23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs

Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routineSAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX:…

Yahoo Finance Mon, 17 Aug 2026

Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor

Nominating and Governance Chair Carol Burt to become Lead Director.Ron Taylor to retire after more than 21 years of service on Resmed’s Board of Directors. SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leadi…

Yahoo Finance Sat, 15 Aug 2026

The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call

ResMed’s second quarter saw steady revenue growth, but the market responded negatively as the company’s operating margin declined year over year. Management attributed the margin compression primarily to higher R&D and supply chain costs am…

Yahoo Finance Fri, 14 Aug 2026

ResMed (RMD) Q4 2026 Earnings Call Transcript

Farrell discusses strategic divestitures, capital returns, and AI digital health expansion.

RMD — Frequently Asked Questions

What is the current share price of ResMed Inc. (RMD)?

As of 2026-09-07 16:24 PDT, ResMed Inc. (RMD) trades at $228.35 on NYSE. Its 52-week range is $182.30 to $290.65.

What is the market capitalisation of RMD?

ResMed Inc. (RMD) has a market capitalisation of $33.12B on NYSE.

What is the P/E ratio of RMD?

RMD trades at a trailing price-to-earnings (P/E) ratio of 23.16. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.74.

Does RMD pay a dividend?

ResMed Inc. (RMD) currently offers a dividend yield of 1.07%.

What is the return on equity (ROE) of RMD?

RMD has a return on equity (ROE) of 25.25%. Its return on capital employed (ROCE) is 23.55%.

Is RMD a good stock to buy?

This page provides a data-driven analysis of ResMed Inc. (RMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space